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Abstract:  
The use of in silico tools within the drug development process to predict a wide range of 
properties including absorption, distribution, metabolism, elimination and toxicity has become 
increasingly important due to changes in legislation and both ethical and economic drivers to 
reduce animal testing. Whilst in silico tools have been used for decades there remains 
reluctance to accept predictions based on these methods particularly in regulatory settings. 
This apprehension arises in part due to lack of confidence in the reliability, robustness and 
applicability of the models. To address this issue we propose a scheme for the verification of 
in silico models that enables end users and modellers to assess the scientific validity of 
models in accordance with the principles of good computer modelling practice. We report 
here the implementation of the scheme within the Innovative Medicines Initiative project 
"eTOX" (electronic toxicity) and its application to the in silico models developed within the 
frame of this project. 
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1. Introduction  
 
The need to develop and utilise reliable in silico models to predict the behaviour of chemicals 
has never been greater. In silico models can be used to predict desired biological activity 
(such as pharmacological effects), toxicity (to human and environmental species) and 
absorption, distribution, metabolism and elimination (ADME) profiles [1-4]. This makes in 
silico approaches very appealing as computational screening approaches during early 
stages of drug discovery. These methods are also applicable to the prediction of properties 
relevant to formulation development and handling of chemicals (e.g. prediction of vapour 
pressure, solubility, melting point etc.) meaning they also play a role in lead optimisation and 
related stages. Models are employed by pharmaceutical, cosmetic, agrochemical and fine 
chemical industries, all of which have financial and ethical reasons for using alternatives to 
animal testing wherever possible. Model development and use are also promoted by 
regulatory agencies with an obligation to reduce animal testing. Legislation such as the 
REACH regulation [5], aimed at ensuring safety of employees and consumers and the 7th 
amendment to the cosmetics directive [6] requiring cessation of animal testing for cosmetic 
products, have further driven the need for alternative methods. 
Whilst the importance of developing and using in silico models has been ascertained, there 
remain barriers to acceptance of predictions based on such models, not least amongst the 
regulatory authorities. Lack of confidence in the validity of a given in silico model (and hence 
predictions based thereon) is a major reason for rejection of such methods. Unlike in vitro 
alternatives, which have a distinct protocol for validation by organisations such as the 
European Centre for the Validation of Alternative Methods (ECVAM) (https://eurl-
ecvam.jrc.ec.europa.eu/), in silico models have not yet been verified in such a formalised 
manner. Given the degree of diversity seen in available in silico models (model architecture, 
statistical analyses used, dataset size and composition, etc.) developing a universal 
approach is difficult.   
Another significant factor that impedes greater acceptance of models is not that the model 
itself lacks validity but the level of detail by which the model is recorded is insufficient to 
allow judgement of model quality; this again means the model cannot be used with 
confidence. Increased acceptance and uptake of in silico modelling approaches will only be 
possible where confidence in the applicability and usefulness of a model to provide a given 
prediction can be assured. In a recent scientific report on modern methodologies and tools 
for human hazard assessment of chemicals the European Food Safety Authority (EFSA) 
highlighted the need for validation of predictive models as an important step in their 
utilisation for chemical risk assessment [7]. Herein, we discuss factors that should be 
considered when assessing the validity of an in silico model, appropriate recording of model 
details and a pragmatic scheme that can be applied for model verification. 
 
1.1  Recent advances and the current stage of in silico model verification 
 
The importance of developing high quality models is well recognised and, despite the lack of 
formal verification schemes, there have been numerous publications relating to best practice 
5 
 
and common errors (and the resulting problems these cause) in model development. Cronin 
and Schultz [8] reported ‘essential’ and ‘desirable’ features for toxicological QSARs. These 
included factors relating to model development, similar to those later identified within the 
OECD Principles for the Validation of QSARs (vide infra) [9], as well as factors relating to 
model use e.g. avoiding extrapolation beyond the original domain of the QSAR and 
appreciating the expected predictivity of the model, when taking into consideration the 
biological data on which the model was founded. Their paper discusses reliable modelling 
practices addressing the three components of a QSAR individually i.e. (i) the biological data 
and their quality, (ii) the physico-chemical descriptors used and (iii) the statistical algorithm 
applied. The paper reinforces the importance of external validation as a means to confirm 
utility of the model. Dearden et al [10] tabulated and discussed (using examples from the 
literature) 21 types of common error in the development and reporting of quantitative 
structure-activity and structure-property relationships indicating which OECD Principle(s) 
were violated by the errors. Recommendations were provided as to how to avoid such errors 
and improve model development and reporting. Stouch et al [11] carried out validation 
studies on four externally derived models using in-house data. Although rationally 
developed, the models performed poorly using the in-house data. Reasons for the apparent 
‘failures’ of the models are discussed by the authors. Problems, such as models being 
developed using inappropriate / highly variable data or data covering a very narrow range 
were identified. The authors make recommendations as to how to improve on the 
development, reporting and use of models emphasising the importance of fully describing 
the data used and the model itself so that the applicability of the model to new compounds 
can be assessed.  
In 2009, Judson [12] proposed a series of rules to be used in establishing good computer 
modelling practice (GCMP), analogous to the good laboratory practice (GLP) rules that are 
applied to ensure high quality of experimental procedures. In addition to highlighting the 
problems of inconsistent interpretation of the OECD Principles, Judson identified the 
additional problems associated with model reproducibility e.g. inadequate information on 
software settings, lack of availability of training or test sets, changes to versions of software 
or availability of programs and lack of suitable documentation for subsequent auditing. 
Thirteen illustrative rules were proposed for GCMP along with 11 illustrative rules to support 
auditing of GCMP. The proposed rules cover a range of issues for example, confirming 
chemical and biological data, providing sufficiently detailed information to allow other 
modellers to repeat tests performed (e.g. parameter and option settings, program versions 
etc), reporting of anomalies, maintaining records of changes to models etc. Problems in 
inadequate recording of modelling procedures were also identified by Kristam et al [13] who 
proposed 12 hypothesis specification requirements that would enable replication of 
pharmacophore models published in the literature.  
The need for developing high quality models and for detailed reporting of the modelling 
process is clear, however progress in developing validation strategies for in silico models 
has been relatively slow. It is more than a decade since the OECD published its principles 
for the validation of Quantitative Structure Activity Relationships (QSARs) for regulatory 
purposes [9]. These principles state that a model should be associated with (1) a defined 
endpoint; (2) an unambiguous algorithm; (3) a defined domain of applicability; (4) 
appropriate measures of goodness-of-fit, robustness and predictivity and; (5) a mechanistic 
interpretation, if possible. Although QSARs are stipulated explicitly, the Principles are equally 
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applicable to other in silico predictive methods. Whilst these principles are based on sound 
scientific philosophy, more guidance is needed on how to apply them in practice to model 
development and assessment. Additional regulatory guidance on the information 
requirements and chemical safety assessment utilising predictive models has been released 
by the European Chemicals Agency (ECHA) [14,15]. Thousands of in silico models have 
already been published within the scientific literature with model development on an 
increasing trajectory due to the necessity to replace animal tests. Furthermore, many models 
developed within the industrial environment remain unpublished, despite being used 
routinely within that setting. What would greatly benefit model developers and users is a 
robust method whereby the scientific validity of models and their suitability for a given 
purpose could be ascertained, such that an end user could have greater confidence in their 
results. 
The inherent quality of the data upon which a model is built is arguably the most important 
characteristic of any model. Data quality here refers to the accuracy and completeness of 
the information on the chemicals studied as well as the adequacy and reliability of the 
experimental data [16,17]. Ensuring the accuracy of chemical structures is not a simple task. 
It is relatively easy to check the basic structure of a compound is correct via a comparison to 
high quality, online resources such as ChemSpider (http://www.chemspider.com). However, 
if the original data source contains an error (for example chirality, ionisation, etc.) this can be 
difficult to identify. In addition, tools such as ToxRTool [18] can be used to help assess the 
quality of both in vivo and in vitro experimental data. ToxRTool provides a series of 
questions relating to experimental information from which a Klimisch reliability score is 
generated - Klimisch scores being the most commonly used methods to assess 
experimental data quality [19]. Although data quality is of paramount importance in QSAR 
development a detailed discussion of quality is beyond the scope of this article; excellent 
reviews of data quality and assessment schemes are already available in the literature [19-
22]. 
A key factor identified from the literature is the requirement for detailed recording of the data, 
model and supporting documentation to enable the validity of the model and its applicability 
for a given purpose to be ascertained. A checklist-style reporting format has previously been 
developed by the European Commission’s Joint Research Centre (JRC, Ispra), known as 
the (Q)SAR Model Reporting Format (QMRF) [23]. This provides a template for recording 
key information about QSAR models and associated validation studies. The format was 
designed with adherence to the OECD Principles in mind. Therefore, this template provides 
a useful starting point for recording relevant model details which can be used to aid the 
assessment of the overall validity of the model.  
Note that the term “assessment of scientific validity” is used herein, this is distinct from 
formal “model validation” processes which may be undertaken, for example, by a regulatory 
authority. Such formal validation would require a more laborious analysis to be undertaken 
and the outcome to be agreed by stakeholders. Here we are concerned with proposing a 
scheme that can be implemented by model users / developers to demonstrate that a 
published model has undergone a rigorous assessment procedure. An alternative 
phraseology would be “peer-verification” of models. Verification is considered here as the 
process by which models are assessed for their compliance with a set of standard criteria 
developed in consultation with model developers and users. The standard criteria reflect 
good computer modelling practice and are independent of the relevance of the model for a 
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particular endpoint. The objective is to develop a “standard operating procedure” (which may 
be confirmed using a checklist approach) to confirm that adequate information has been 
recorded about a given model to enable it to be accurately reproduced and judgements to be 
made on the statistical reliability of the model. This allows a user to determine the model’s 
suitability for predicting behaviour of other chemicals (e.g. whether or not a new chemical 
would fall within the applicability domain of the model). This would enable users of models to 
have more confidence in predictions based on the models and a greater appreciation of 
which models are (not) suitable for a given purpose.  
The process of “peer-verification” was considered as being key for increasing user 
confidence within the European Union Innovative Medicines Initiative eTOX project, which is 
described in detail below [24,25]. Whilst the work reported here was carried out as part of 
the eTOX project, the assessment scheme developed was designed to be universally 
applicable. Extending beyond regulatory acceptance, it is also anticipated that the 
verification scheme could have a role in developing rules for peer-reviewing models 
submitted for publication in scientific literature. Currently, the quality of predictive models 
submitted for publication is variable, with the editor/reviewer having to assess whether a 
given model is valid and suitable for publication. The development of a verification scheme, 
as detailed here, could be used, not only by model developers and regulatory bodies, but 
also by the aforementioned editors and reviewers to inform on the scientific validity of a 
given model. 
The aim of this paper is to provide a scheme, for model developer, users and the wider 
scientific community, which can assess the validity of in silico models. This paper provides a 
harmonised method for peer-verification of models, ensuring where possible the OECD 
Principles are met and good computer modelling practice is followed to maximise confidence 
in predictions based on the models. Emphasis is placed on accurate and detailed 
documentation to accompany the models, as insufficient information is acknowledged to be 
a significant barrier to acceptance. 
 
1.2 eTOX project overview 
 
The eTOX (“electronic toxicity”) project is a joint collaboration between the European 
Commission and the European Federation of Pharmaceutical Industries and Associations 
(EFPIA) as a Joint Technology Initiative under FP7 (http://www.etoxproject.eu/). The eTOX 
project started in January 2010 for a duration of 5 years. The international project consortium 
consists of 13 pharmaceutical companies, 7 academic institutions and 6 SMEs with a total 
budget of €13.9M. The aims of the project are to develop a drug safety database from the 
pharmaceutical industry legacy toxicology reports and public toxicology data, build 
innovative in silico strategies and novel software tools to better predict the toxicological 
profiles of small molecules in early stages of the drug development pipeline. It is anticipated 
that wider uptake of a model verification process will increase confidence in, and therefore 
greater acceptance of, the in silico models built within the project. 
 
A major output of eTOX is an online prediction platform known as eTOXsys, which contains 
not only a searchable version of the database, but also access to all the models developed 
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within the project (currently access is restricted to project partners). At the time of writing the 
database contains over 1700 structures linked with over 6000 repeat dose studies, and the 
models available cover a range of endpoints including cardiotoxicity, hepatotoxicity, 
phospholipidosis and many others. These models are developed from the available public 
data and, in some cases, with confidential data supplied under agreement with industrial 
partners. These data have been extracted from legacy toxicological reports and developed 
into a large database to advance in silico drug-induced toxicity prediction [25, 26]. 
 
Given the project extracts, collates and models both public and industry toxicological data, a 
critical component of the eTOX project has been to research and construct a strategy to 
assess the scientific validity of the models it develops. This strategy is a significant output of 
the project in itself, since no comprehensive verification scheme has yet been published. 
2. Development of the Assessment Scheme 
 
Several factors were considered to be of key importance in developing the assessment 
scheme to be used for model verification: (i) carrying out an assessment of a model had to 
be a realistic task both in terms of the required expertise of the individual and the time 
needed to conduct such an assessment; (ii) the assessment criteria had to be presented in a 
format which would be compatible with a wide range of operating systems and software and; 
(iii) the verification process had to be transparent, scientifically justifiable and the results 
readily accessible to end users. 
The OECD Principles currently represent the state-of-the-art in terms of model validation and 
the QMRF is a well-recognised method for recording key information concerning models. 
Therefore the OECD Principles and the QMRF documents were used as the starting point 
for further development of the model assessment scheme described herein. The developed 
scheme also drew on the rules proposed by Judson [12] for GCMP to ensure that the 
models themselves were scientifically valid in addition to being correctly recorded. 
Modifications were made to the existing QMRF in order to: 
 Extend the scope of the criteria beyond those appropriate only to QSAR models, to 
yield a set of criteria applicable across a wider range of in silico modelling methods 
 Provide additional guidance to the user on how to assess each individual criterion. 
In addition to the development of the criteria themselves, a key element of the current work 
is that it proposes a peer-review style model verification protocol, where external model 
verifiers perform robust model assessments using the aforementioned criteria. To help 
support this, additional functionalities such as dataset/model repositories, verification 
datasets and detailed guidance documents are introduced and discussed.  
 
2.1 Peer-Verification 
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A novel component of this approach is the introduction of a peer-review aspect to model 
verification. This is not to say that an external verifier is responsible for all aspects a model’s 
successful verification. We propose that model builders themselves prepare and submit all 
required documentation and supporting data, such that an external verification can be readily 
carried out. The role of the model verifier is then to check the submission for accuracy, 
completeness and reproducibility.  
There are several possibilities regarding who could take responsibility for model verification. 
Researchers in the modelling community could undertake verification of each other’s models 
in the spirit of cooperation, so that greater confidence is built in published models. Users 
within industry, who have an interest in the applicability of models to their chemical space of 
interest, could also be involved in verification. Within larger projects, for example European 
project consortia the task of model verification can be distributed amongst partners. There is 
also the possibility of international organisations such as the Joint Research Centre, QSAR 
DataBank (www.qsardb.org) [27] or the OECD playing a role in verification, perhaps being 
appointed by regulatory bodies themselves to further increase acceptance. 
In the initial stages of developing the concept of peer-verification it was important to have the 
input of both modellers and end-users who could comment on the process as it was being 
established, and advice on improvements in an iterative manner. The peer-verification 
process was developed here in collaboration with partners on the EU eTOX project. There 
were several advantages to this: many models were under development within the project 
enabling a range of model types to be put forward for the pilot verification process; one 
partner could act as a coordinator liaising between model developers and verifiers; a large 
project team was already working together in model development; end users could have 
direct input into model verification identifying features that were most important to them; an 
“honest broker” (Lhasa Limited, Leeds) was available to perform peer-verification on models 
that were built using confidential data. Part of the peer-verification process requires 
investigation of the data used to build the model, where confidential data are used in model 
building alternative solutions have to be considered. In this case a trusted third party could 
access the data; this approach may be adopted for other models where the model builder 
can identify a trusted third party as verifier or the builder would need to provide assurance 
that adequate checks have been made concerning the data. 
In silico models that were available within the eTOX project were put forward for verification 
using a proposed model verification schema. An overview of the process is given in Figure 1.  
 
INSERT FIGURE 1 HERE 
 
The criteria used for assessment represent an amalgamation of the OECD Principles, the 
(Q)MRF documentation requirements and elements of GCMP, as identified by Judson [12].  
It was a prerequisite that the verification criteria were delivered in an open format, accessible 
by all end users. It was agreed that Microsoft Excel would be used as most users have 
access to this software or the file can easily be reformatted as a simple text file (e.g. csv) for 
input into other tools if needed. Since it was anticipated that verification documentation 
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would be archived and remain accessible to end users upon completion, this file format also 
benefits from relatively small file sizes. A checklist style architecture was adopted for 
simplicity, with the aim to enable a rapid (tick box) verification to be performed where 
possible. The verifier’s role is to ensure that all of the required information is present and 
appropriate. A front cover page (worksheet) was created to record details of the model, its 
developer and verifier. In addition, the main aspects of the verification process are 
summarised and fields are created to house any comments or questions arising following 
verification (Figure 2). 
 
INSERT FIGURE 2 HERE 
 
The checklist details all of the criteria to assess as well as a short text field to provide 
additional notes relating to each criterion. It was intended that the single file would contain 
the criteria, be completed by the model verifier and then be made available to show the 
verification status of a given model. 
Model verification is underpinned by comprehensive model documentation. As discussed 
previously, one of the major limitations to model acceptance at present is the lack of 
sufficiently detailed model documentation. Basing the information required for model 
verification on the criteria required for the JRC’s (Q)MRF template alleviates this problem, as 
it was specifically designed to collect all of the information needed to assess a model’s 
adherence to the OECD Principles. The complete verification criteria, termed the “verification 
template”, used here (developed in collaboration within eTOX project) are available as 
supplementary material. In an effort to make the verification criteria both easy to complete 
and also easy to review, it was decided to split the criteria into three sections ((i) – (iii) 
below), each covering a different aspect of validation. 
2.1.1 Model Documentation 
 
This section forms the backbone of the verification criteria and consists of a range of 
questions relating to model documentation. This is the most important aspect of the 
assessment since it is contains all of the modelling details and supporting statistics. This 
section covers aspects relating to:  
 A model’s identity and its developers 
 The endpoint investigated 
 Training/test set data (including source) 
 Modelling algorithm and summary statistics 
 External predictivity 
 Mechanistic information 
 Applicability domain 
 Interpretation of prediction 
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There should be sufficient detail within this section, not only to assess the model in terms of 
the OECD Principles, but also to rebuild the model. Any uncertainties arising during model 
verification should be addressed with the model developer. In terms of scientific validity, the 
documentation represented here should contain sufficient details to identify any potential 
issues resulting from application of inappropriate statistical approaches, overtraining of 
models, limitations in domain of applicability, etc. 
 
2.1.2 Data Used to Build the Model and Consistency of Model Output 
 
The nature and quality of data used to build a model is a major determining factor in model 
acceptability. It was therefore considered prudent to include an assessment of the dataset(s) 
used to develop a model as part of the verification process. Missing or incorrect data are 
recognised as major problems within model development [8, 10]. Unless prohibited for 
reasons of confidentiality, dataset(s) used to build (and test) a model should be available to 
the verifier. The information (which can be provided in the form of an Excel spreadsheet) 
should include chemical structure data (e.g. chemical name, SMILES strings), known 
(experimentally determined) endpoint values and endpoint values as predicted by the model 
in question. Knowledge of what the predicted values should be is required for assessing 
model implementation. 
A major consideration in data quality is confirmation of the accuracy of the chemical 
structures contained within the data files submitted for model verification. Inaccuracies in 
chemical structures are one of the most common sources of error within computational 
modelling [16, 17, 28]. If these structures are incorrect (in terms of their chemical 
composition, ionisation, chirality, etc.), the error is carried across into the predictions making 
them unreliable. Whilst checking all structures within a dataset may be impractical for large 
datasets, a representative sample of data (for example 5 or 10% of structures can be 
checked using appropriate databases (such as ChemSpider)). If a problem is identified when 
checking a small number of structures then the remainder of the dataset can be checked. 
Another option would be to utilise freely accessible tools developed and supported by public 
organisations, such as OCHEM (www.ochem.eu) [29]. OCHEM has the functionality to 
rapidly screen a dataset (chemical name and structure) against PubChem and additionally 
applies methods to check for structural correctness. Structures that are suspected of being 
incorrect are then highlighted to the user for further examination. The same features as 
implemented in OCHEM are available within QSPR Thesaurus database [30] which, whilst 
more focused on the estimation of environmental toxicity, is a useful tool for identifying 
hazard. This approach dramatically reduces the number of manual checks that need to be 
performed by the mode verifier, enabling the entire dataset to be assessed, increasing the 
quality of modelling datasets. Of course, since this is a web-based tool, it is not suitable for 
assessing the quality of confidential data. 
Quality of experimental data can be assessed using criteria, such as Klimisch scores [19]. 
However assessment of experimental data is a complex task and a detailed discussion is 
beyond the scope of the current work. As mentioned previously, for models containing 
confidential data, an “honest broker” can be assigned. This trusted third party could access 
the data and perform the verification checks required. This approach may be adopted where 
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the model builder can identify a trusted third party as verifier or the builder would need to 
provide assurance that adequate checks have been made concerning the data. 
 
2.1.3 Implementation of the Model 
 
The final component of the assessment criteria relates to how a model is implemented. For 
example, if a model is made available as a web service or is recommended to be 
implemented using specific software then the infrastructure for implementation needs to be 
confirmed as being stable and capable of providing reproducible results for different users. 
 
In terms of the eTOX project, each model is made available via a web-based platform. 
Where confidentiality is an issue (e.g. for industrial partners), the project also implemented 
its predictive capabilities within a virtual machine environment that could be installed locally 
behind their firewall. Therefore, in this case it is necessary to ensure that a model is 
functioning as intended within the eTOX platform. Three aspects were considered here for 
model implementation: 
 
I. Model stability – Here, the model is tested to ensure the model functions and 
returns predictions in all cases. Any issues relating to descriptor calculation error, 
problem structure(s) or more general software problems are quickly detected utilising 
a predefined dataset containing a selection of “common” structures. In the case of 
the eTOX project these structures were designed to include commonly encountered 
drug types and associated moieties. A validation set is designed to represent the 
types of compounds an end user may routinely analyse using the model. 
II. Robustness to input files – The second stage is to assess a model’s robustness to 
a dataset containing structurally diverse compounds covering a broad spectrum of 
structural domains and molecular weights. Any sensitivities or limitations of particular 
models/software would be exposed under this more rigorous analysis of a model’s 
applicability 
III. Consistency of output – This final stage is designed to check that a model returns 
what is expected and is functioning as intended. There are two parts to this step: 
a. When using the model’s training or test set, do the predictions generated by 
the model match the expected output provided by the model developers? 
b. Does the model generate the same output when the same structure is given 
in multiple formats? For example, differing SMILES notations for the same 
compound or when comparing the output given by structure input files of 
different formats. 
Outside of the eTOX project, the possibility exists for modellers to upload models onto 
publically accessible online resources, such as QsarDB (http://www.qsardb.org/) [27] or 
OpenTox (http://www.opentox.org/) [31]. In addition to the actual models, these resources 
are also able to store modelling datasets, model documentation, model predictions, etc. This 
functionality provides an ideal platform from which to conduct model verification studies 
13 
 
since it allows full access to the model and all of the related information. Furthermore, it may 
also be possible for these systems to automatically generate summary statistics based on 
the datasets provided, increasing consistency and negating the need for modeller/verifiers to 
calculate these values themselves.  
For any predictive model implemented in any accessible system or tool, sustainability of that 
platform is a key factor to consider. In terms of eTOXsys (and any other web-based platform) 
it is initially developed and then maintained only for a specified period of time. Depending on 
subsequent usage, this period may be extended, but the life of a particular online system or 
tool is uncertain. If the system is deleted (or access restricted) the model(s) are therefore 
lost. This in no way is berating the importance of online resources and tools, but inevitably 
their usefulness diminishes with time with the release of new tools and data. A possible 
solution to ensure that models are not lost is again to upload them onto publically accessible 
resources including QsarDB [27] and OpenTox [31]. An additional resource suitable for this 
purpose is the Joint Research Centre’s QSAR Model Database 
(http://qsardb.jrc.ec.europa.eu/qmrf/). Their upload to and storage on such repositories 
ensures that models are preserved and can be accessed for future use. 
Given the multitude of differing modelling approaches now being utilised, the verification 
template was intentionally developed as a non-prescriptive, flexible document. It was 
anticipated from the outset that not all fields would be applicable in all cases and that certain 
fields were open to interpretation by different modellers and verifiers. For example, 
applicability domain definition may be determined in different ways depending on the 
modelling approach (e.g. QSAR model versus the use of structural alerts). 
It was anticipated that iterative refinement of the peer-verification process would be 
necessary. Therefore, once a draft procedure for verification had been devised (as described 
above) a pilot study was carried out, within the eTOX project, to determine necessary 
amendments (e.g. what steps would be needed to improve the process, was additional 
guidance documentation necessary, etc.). For the pilot study a diverse set of ten models was 
selected; this contained models that employed different algorithms, endpoints, dataset 
characteristics and differing model developer backgrounds (industry, academic etc.). Ten 
appropriate model verifiers were assigned (based on their expertise in the area) and the 
results of this pilot study were used to refine the verification process. It must also be noted 
that the eTOX project is made up of EFPIA (European Federation of Pharmaceutical 
Industries and Associations) and public partners. Both of these user groups were 
represented in the choice of model verifiers. Each model verifier was provided with the 
information and documentation detailed by Table 1. 
 
INSERT TABLE 1 HERE  
 
To highlight the diversity of the modelling approaches covered with the pilot study and the 
applicability of the devised verification protocol and documentation, the ten pilot study 
models developed within eTOX are summarised by Table 2. 
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INSERT TABLE 2 HERE  
 
Those involved in the pilot study were invited to comment on the operation of the peer-
verification scheme. Following feedback received, an improved scheme for model 
assessment was devised. The outcome of the pilot study and the resulting new schema are 
discussed below. 
 
3. Results of pilot study 
 
The aim of this work was to devise an assessment scheme to enable peer-verification of in 
silico models, such that end users could have greater confidence in accepting predictions 
based on such models. A pilot study using a draft scheme was carried out within the eTOX 
project, the results of which were used to inform the next stage of development of the peer-
verification process resulting in a schema with broad applicability to a range of in silico 
models. 
The pilot study was extremely informative as it gave an insight into how the verification 
process fared in a real-world situation. It highlighted a range of issues, some predictable and 
others which were unanticipated; this information was critical to the refinement of the 
verification process. During the initial pilot study none of the ten models selected were 
successfully verified. The reasons for this partly relate to problems within the verification 
process (which will be discussed in more detail below) but also to the fact that the modellers 
were not aware of the verification criteria when they began developing models. Thus, critical 
information was missing in certain cases because specific steps were not taken during 
model development. The second reason why models could not be verified during the 
process related to the inexperience of the verifier. As this was a new process for all parties 
involved, certain aspects of the process were not communicated in sufficient detail. 
Misunderstandings led to misinterpretation of the criteria and hence models failed in areas 
where all the information was available but the verifier did not know where/how to access the 
relevant information. These issues were identified within the feedback provided by the 
verifiers which forms the basis for the results of this analysis and the focus of the remainder 
of the paper; performance of individual models and their verification is not discussed further. 
 
3.1 Feedback on the verification process 
 
Overall, verifiers stated that they were satisfied in general with the model verification process 
and the tasks involved. However, they reported confusion regarding some areas of the 
documentation which led to them being unable to complete some of the tasks.  
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3.1.1 Data used to build the model 
 
Assessing the dataset(s) used to develop and test predictive models is a key element in the 
verification process. The main problems found when assessing data quality in this study 
related to the format of the provided data. There was no consistency between the modellers; 
each supplied the data in their favoured format (InChi, SMILES, SDF etc.) and also supplied 
varying levels of detail (e.g. which compounds were used as test or training data, their 
predictions from the model, their experimental results etc). Therefore, an obvious solution 
would be supply modellers with a standard template with which to submit the required data. 
The second factor of assessing data quality was to check the validity of the structures 
provided. This can be an extremely difficult and time consuming task if all the structures 
within a supplied dataset are to be verified. Therefore, only a sample of the structures was 
required to be verified. However, the feedback from the verifiers still highlighted this as the 
most time consuming task of the whole process. Methods implemented to complete the task 
included performing manual checks on a small percentage of the dataset (e.g. 5%), 
comparing the InChi-keys generated from the provided structures versus those obtained 
from ChemSpider (using CAS numbers) and crosschecking the SDfile against UNICHEM 
Cross Reference Code. Verifiers also commented in a number of cases on the lack of 
stereochemical definition in structures. This would become important when different 
stereoisomers display different biological activities. If stereoisomerism information was 
lacking, a model would be insensitive to any differences between two stereoisomers.  
The final factor which should be examined is the accuracy of the activity/endpoint data. This 
aspect of data quality was not assessed in the pilot study because it was outside the scope 
of the verification work. It is important to assess experimental data quality at the modelling 
rather than verification stage as models should not be built using poor-quality data. 
Modellers then need to describe how they have assessed the quality of their training (and 
test) data in the model documentation. The verifiers would then simply need to check that 
this information is available. An example of high quality data suitable for modelling is the 
central eTOX database. Here, the data underwent a strict routine of tests and checks before 
being entered into the central database. As discussed by Przybylak et al [22] completing 
data evaluation at the data curation stage is easier as modellers do not need to look back 
through historic reports or publications to find the data which is relevant. However, it should 
be noted that although the data was checked by the donating partner for correctness against 
the original study report and GLP status are provided; no global description of quality was 
assigned to the data. Also, the models used in the pilot study had not been produced using 
the main eTOX database. 
3.1.2 Model Documentation 
 
This is an area where all of the pilot study models failed the verification process. The issues 
found with the model documentation were often minor and consisted of typing errors and 
discrepancies between the data supplied by the modeller and the formal documentation in 
terms of reported statistics, number of compounds etc. There were also reports where the 
information provided were too vague to be useful to the end user and would benefit from 
additional clarification. 
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The largest problem with the model documentation was the presence of multiple missing 
entries where no information had been provided (i.e. the fields had simply been left blank). In 
many cases the fields were not applicable to the model under investigation but the verifier 
could not know if this was the case or if the field had been missed. For example, when 
considering structural alert models with qualitative endpoints (e.g. positive/negative), certain 
quantitative goodness of fit criteria (R2, RMSE, etc.) are not applicable. 
Some reporting errors were expected but it was surprising that all of the models in the pilot 
study failed in this area. This highlights the importance of fully involving the modellers in the 
verification process. If they were aware of the specific elements which were going to be 
analysed during verification, they may have prepared their documents differently and been 
more successful during verification. Subsequent improvements to this process are discussed 
later.  
The applicability domain and reliability of each model should be described in the model 
documentation so that the model is compliant with the fourth OECD validation principle. This 
information should show the user where a model can be used to make reliable predictions 
and act as a guide/warning to end users. However, it was found that most models within the 
pilot study did not have any assessment of the applicability domain. This was not totally 
unexpected since the version of eTOXsys in use at this time did not support models 
providing applicability domain information (such information needed to be added as part of a 
models eTOXvault entry). However, it was surprising to see that most models lacked even 
basic applicability domain information. This is a major problem and needs to be rectified for 
all models. The exceptions to this were the structural alert models for which the applicability 
domain is inherently described: the presence of an alert within a compound dictates that the 
compound is within the applicability domain of the model. It must be remembered that the 
applicability domain is a complicated issue with many different approaches one can take in 
its definition. Even for the aforementioned structural alerts models, defining the applicability 
domain can be a complex task [32]. Within eTOX, the new release of eTOXsys is now able 
to accept applicability domain information, aiding in its characterisation. At the same time, 
work is ongoing within the project to develop tools able to assess a models applicability 
domain (e.g. ADAN [33]). 
3.1.3 Implementation of the Models 
 
Model implementation during the course of the eTOX project is via a bespoke web-based 
platform eTOXsys. Upon completion of the project, a fully deployable, self-contained system 
is envisaged. This online system used to run the models and return predictions in the pilot 
study was found to be stable under these test conditions. This is a significant achievement in 
itself considering the complex architecture of the system and that it relies on input from many 
independent researchers (Fig. 3). The only two points raised with regard to the stability of 
the eTOX system were the enforced maximum size of the input files, which was smaller than 
some of the test sets, and also problems with SDFiles created in specific software. The first 
problem was easily rectified by the developers simply increasing the maximum file size 
allowed by the system. The second issue related to a specific bond type created by third 
party software (namely the aromatic type ‘4’ bond created by the ChemAxon, MarvinBeans 
suite of tools (http://www.chemaxon.com/products/marvin)). Therefore, the solution to this 
was to either not use ChemAxon for generating SDFiles or to the use the “Convert to 
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Kekulé” function with Marvin. Whilst the issues identified were clearly specific to the 
eTOXsys platform, the study highlights that whichever system/software is used for model 
implementation, it needs to be assessed as part of the model verification process. 
 
INSERT FIGURE 3 HERE 
 
Although stable, some models were unable to make predictions in all cases due to their 
inability to generate required molecular descriptors. It must be said that this was 
encountered rarely (for a single compound), but it did result in all compounds within a 
dataset receiving an error rather than a prediction. It is understood that more complex 
compounds may, sometimes, cause a failure in the calculation of certain parameters. 
However, in this study it was only the training, test and verification datasets that were being 
considered which rarely contained any exotic compounds. Within the pilot study, one 
exception to this was a compound containing co-ordinate bonds which lead to multiple 
prediction failures. Such failures here suggest possible issues in relation to model 
robustness and applicability that should be made clear to the user. 
In addition to missing predictions, it was also noted that the predictions generated by 
eTOXsys did not, in all cases, match those provided by the model builder. Such differences 
could be a result of the model verifier altering the input file in some way. This could include 
splitting the input file to overcome the input file size restriction or as a result of a verifier 
transforming the input file format (e.g. from SMILES to InChI). In addition, there could be 
problems resulting from how the model was implemented within eTOXsys. It is also possibly 
that erroneous predictions were provided by the model builder but this issue is easily 
resolved where model builders and verifiers are working together. 
In addition to points raised above, three further issues were also raised by the verifiers. One 
of these was specific to the project but 2 others have a wider applicability and are hence 
discussed here: 
I. How do we know that the verifiers are performing the process correctly? 
II. The verification protocol examines model validity, but not whether the model is fit for 
a given purpose 
The first point was easy to answer as the entire verification process was co-ordinated, in this 
case, by the verification co-ordinators who could check all incoming verification reports for 
accuracy and consistency. They were also there to act as an intermediary to enable 
communication between the modeller and verifier where required. Outside of projects where 
it is possible to have a verification co-ordinator, it is envisaged that a peer-review system 
similar to that used by scientific journals could be used. Modellers and verifiers would work 
together to ensure that verification is completed in a satisfactory manner. 
The protocol described here intentionally only examines model validity and not whether the 
model is fit-for-purpose. This is because whether a model is fit for a specific purpose can 
only be determined by the end user (i.e. a model may be appropriate for one purpose but not 
for another – this does not reflect on the intrinsic quality of the model). In terms of eTOXsys 
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it is envisaged that it will be used by a variety of end users and therefore it is impossible for 
one or a group of parties to state which models are the “best”. This philosophy also applies 
outside of the eTOX project where model developers and end users may be working from 
very different perspectives. Information should be available to end users to help them to 
make the decision for themselves (i.e. description of endpoint, data used to build model, 
statistics etc.). A global fit-for-purpose assessment is not appropriate. 
 
3.2 Lessons Learnt 
 
The feedback provided from the pilot verification study clearly highlighted areas for 
improvement. The most important issue was the need for clear guidance for the verifiers. 
This study used a variety of verifiers from different institutions which led to variability in the 
way the verifications were completed and hence the information that was reported in the 
verification template. This problem could be easily rectified by providing clear, concise 
guidance documents to verifiers. The documents would state how to perform each stage of 
the verification and what is (not) acceptable in the fields of the model documentation. They 
would also detail which data should be used for testing and whether verifiers need to 
reproduce any reported test statistics. 
Another lesson learnt was the amount of missing information the verifiers found in the model 
documentation. It became apparent that modellers need to know what is required for 
verification at an early stage so that they can ensure this information is available. It should 
not be presumed that they will automatically provide all the required information. For 
example, in this study, along with modellers not entering ‘N/A’ for fields not relevant to their 
models, they often omitted the following information:  
 
 Definition of the applicability domain 
 Mechanistic basis of the model 
 Description of the types of compounds used to build the model (e.g. pharmaceuticals, 
small industrial chemicals) 
In addition to the specific guidance required for verifiers, it became clear that further 
guidance on assessing data quality was required. This is in terms of checking the structures 
in both test and training set data, and whether or not to assess the quality of the 
experimental data. The method for checking structural integrity was chosen by each specific 
verifier, but this again led to variability in the results and also left some verifiers unsure how 
thorough to be with the task (e.g. is stereochemistry important for all models?). Therefore, it 
would be useful to provide a standard set of instructions on the specifics of assessing 
structural accuracy. It may also reduce the time taken to perform this task which was a 
concern to some of the verifiers. 
Assessing experimental data quality is another important yet time consuming task, as 
previously discussed. Therefore it is important, as stated above, to provide verifiers with 
enough information on the topic to allow them to fully understand what is (not) required. 
Although experimental data quality was not examined in this study (due to the constraints of 
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the project) it is something which would be required if this verification scheme is to be used 
on a larger scale. As the initial use of the data is by the modellers, it would seem logical that 
the data quality is assessed at this stage, rather than during verification. A model builder can 
comment on how they have arrived at the decision that particular data are suitable for their 
purpose (e.g. experiments were performed according to GLP, database is highly curated). 
Therefore, one can envisage the data quality assessment being included in the model 
documentation. A standardised system would need to be agreed but something akin to the 
Klimisch [19] scheme could be implemented by modellers when they build their models and 
the verifiers would then only need to check whether the information has been made available 
in the model documentation. 
 
4. Development of a Revised Assessment Scheme for Peer-Verification of Models 
 
The lessons learnt during the pilot study have enabled us to make improvements to the 
verification scheme devised and to suggest a practical final scheme for the verification of 
predictive computer models (Figures 4-5). It is expected that the co-ordination aspect would 
be completed by a verification co-ordinator (as for the eTOX project) or split between the 
modeller and verifier. The scheme is implemented through four documents: 1) Model 
documentation along with field descriptions; 2) Data template for submission of data to 
verification; 3) Verification template for verifiers; 4) Guidance document on how to complete 
verification (Standard Operating Procedure). All of the documents are available as 
supplementary information and are also described below. 
 
INSERT FIGURE 4 HERE 
INSERT FIGURE 5 HERE 
 
4.1.1 Model documentation along with field descriptions 
 
The new model documentation retains the sections described in section 2 but field 
descriptions were made easily available to the modellers to allow them to better understand 
which fields were relevant for their models. This enables them to complete the 
documentation more thoroughly and indicate non-relevant fields with ‘N/A’.  
 
4.1.2 Data template for submission of data to verification 
 
The data template retained all of the fields described in section 2 but now stipulates that only 
SMILES can be used to submit compounds to overcome conversion problems encountered 
with InChi codes. This also negated the requirement for modellers to submit compounds as 
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SDfiles as there are a number of software packages (freely) available to perform a 
SMILES/SDF conversion. 
 
4.1.3 Verification template for verifiers 
 
The three main sections of the verification template remain but the order has been changed 
to make the process more efficient and to ensure verifiers do not need to repeat tasks when 
information is required in the different sections. The order of the template is now: 
I. Assessment of data 
II. Assessment of model implementation 
III. Assessment of model documentation 
Additional information has also been added to the template to provide guidance on what the 
verifier should be examining for each statement. For example, the ‘accuracy of structures’ 
statement is accompanied by the following information “Datasets should be checked for 
agreement between chemical name, CAS, structure, etc. Any disagreement should be 
reported.  A suggestion is to rank compounds via endpoint value and assess every 20th 
compound (5%), depending upon dataset size. The methodology implemented to assess 
structure accuracy is dependent on that available to the individual model verifier. As a 
minimum requirement, the structures within the dataset (or subset) should be compared to 
those within high quality online chemical databases, e.g. ChemSpider. Other suitable 
approaches may also be used.” 
The verification checklist remains as a useful tool for enabling the verifier to review all of the 
verification statements and assess whether a model should be considered ‘verified’. This 
allows for the verifier to use their discretion where a model may have failed some 
insignificant criteria but they still feel the model should be given the verified status. For 
example if one or two of the statistics on model performance are missing but enough 
information is provided to give the user an understanding of model performance, then the 
verifier might perceive it to be appropriate to state that adequate performance statistics are 
provided and sign off the model as verified. 
 
4.1.4 Guidance document on how to complete verification 
 
This document can be used alongside the verification template to provide verifiers with all 
the information they require to complete the process. The verification process is described in 
four stages which relate to the three sections of the verification template. Additional actions 
which are (not) required for each stage are also described here. For example, it is noted that 
the verifiers need to convert the SMILES provided to SDFiles to run them through the 
models, and that it is not necessary to run all the test and training data through the model 
during stage 1 as this stage simply requires the presence of the data to be noted. Although 
some of these instructions seem obvious they have been included to ensure that 
assessments are consistent across numerous verifiers. 
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5. Conclusions 
 
The requirement for predictive in silico models to be verified for use, particularly in regulatory 
settings, is clear. Work published over the past 10 years has shown how important this task 
is, but as yet there has been little practical guidance on how this might actually be achieved. 
The work presented here has provided a clear scheme for model verification which can be 
applied across a variety of model types (e.g. structural alerts, QSAR, molecular interactions). 
The pilot study showed clear areas of improvement which have now been implemented 
within the eTOX project. The pilot study allowed initial ideas about the verification process to 
be tested and refined without impacting heavily on the on-going work of the project. It 
became obvious that it is not sufficient to supply verifiers with a single document to be 
completed. A standard operating procedure needs to be implemented to give modellers and 
verifiers a clear understanding of what is required. A graphical representation of the SOP is 
shown in fig. 4-5.  
Overall testing ideas through the pilot study allowed a clear and concise scheme for model 
verification to be developed. These modifications are currently being tested within the eTOX 
project as the scheme described above is being used throughout the project to verify all 
models which have been produced. Once the verified models are available to users and 
there is a practical use-case, it is hoped that value of this work in a regulatory setting will 
become apparent.  
In summary, the method for peer-verification of in silico models, as presented here, may be 
applied in a broad range of modelling scenarios and applied to other areas such as the 
evaluation of models submitted for publication. It is intended that using such a scheme to 
assess the scientific validity of models, will increase acceptance of the models and engender 
greater confidence in predictive methods. 
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Figure Legends: 
Figure 1. General overview of the proposed model verification process. 
Figure 2. The verification checklist to be completed by verifiers. 
Figure 3. Basic architecture of how models are implemented in eTOXsys. 
Figure 4. Overall process of model development and verification. 
Figure 5. Specific requirements of the verifier 
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Table 1. Summary of the resources and brief provided to each model verifier participating the 
verification pilot study. 
 
Provided to the verifier Verifiers Brief 
An email containing: 
 The identity of the model to be 
verified. 
o Model name and eTOXsys 
ID 
o Model developer 
 The model verification template 
 The relevant model training/test sets 
 The expected model predictions 
Each verifier was asked to use the verification 
template provided to assess the model they 
were assigned. 
All verifiers had been involved in developing 
the draft template to some degree and had 
seen this document beforehand. 
Each modeller was given two months in 
which to perform the verification task. 
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Table 2. Summary of the model types participating in the eTOX verification pilot study. 
 
Model 
ID 
Model Type Endpoint 
Model 
Developer 
Model Verifier 
1 kNN CYP 3A4 affinity Chemotargets Novartis 
2 
Decision tree and 
3D QSAR 
Drug-induced 
phospholipidosis 
Fundació 
IMIM 
Bayer 
HealthCare 
3 
Ligand-based 
pharmacophore 
hERG inhibition 
Inte:Ligand Dutch Technical 
University 
4 
Ligand-based 
pharmacophore 
Acetylcholinesterase 
inhibition 
Inte:Ligand GlaxoSmithKline 
5 Expert system Hepatotoxicity Lhasa Limited Lhasa Limited 
6 Structural alerts 
Drug-induced 
phospholipidosis 
Liverpool 
John Moores 
Univesity 
Molecular 
Networks 
7 
Classification 
SVM 
Plasma protein binding 
Lead 
Molecular 
Design 
Vrije Universiteit 
Amsterdam 
8 Consensus kNN Human total clearance 
Molecular 
Networks 
Fundació IMIM 
9 Consensus kNN 
Drug induced 
phospholipidosis 
Molecular 
Networks 
Chemotargerts 
10 Decision tree 
Predominant CYP 
isoform (3A4, 2D6 and 
2C9) 
Molecular 
Networks 
Liverpool John 
Moores 
University 
 
 
